Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
77 hedge funds and large institutions have $330M invested in Harpoon Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 14 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $341M → $330M (-$10.7M)
3% less funds holding
Funds holding: 79 → 77 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
75% less call options, than puts
Call options by funds: $674K | Put options by funds: $2.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.56M |
| 2 |
Millennium Management
New York
|
+$2.8M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$2.15M |
| 4 |
JP Morgan Chase
New York
|
+$1.25M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.43M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.98M |
| 3 |
Renaissance Technologies
New York
|
-$1.87M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$889K |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$722K |
HARP Hedge Fund Activity: Q4 2020 in Review
77 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q4 2020, worth a combined $330M — down 3.1% from $341M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of HARP and 12 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 23 added.
The largest buyer was BlackRock, adding an estimated $3.56M. The largest seller was Point72 Asset Management, cutting an estimated $6.43M.
- 77 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q4 2020, down from 79 in Q3 2020.
- Funds reported $330M of Harpoon Therapeutics, Inc. Common Stock stock for Q4 2020, down 3.1% quarter-over-quarter.
- 12 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q4 2020 and 14 closed out, a net change of -2 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q4 2020 was BlackRock, an estimated $3.56M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q4 2020 was Point72 Asset Management, an estimated $6.43M sold.
Based on aggregated 13F filings for Q4 2020.